Protalix BioTherapeutics, Inc.
PLX
$2.80
-$0.055-1.93%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.44% | 33.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.44% | 33.29% | |||
| Cost of Revenue | -53.60% | -11.43% | |||
| Gross Profit | 49.54% | 138.53% | |||
| SG&A Expenses | 15.57% | -25.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.18% | -12.16% | |||
| Operating Income | 80.63% | 264.44% | |||
| Income Before Tax | 90.37% | 269.15% | |||
| Income Tax Expenses | 35.42% | 979.71% | |||
| Earnings from Continuing Operations | 100.68% | 246.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.68% | 246.89% | |||
| EBIT | 80.63% | 264.44% | |||
| EBITDA | 74.61% | 304.93% | |||
| EPS Basic | 110.23% | 246.18% | |||
| Normalized Basic EPS | 99.08% | 268.56% | |||
| EPS Diluted | 88.72% | 211.96% | |||
| Normalized Diluted EPS | 47.97% | 252.58% | |||
| Average Basic Shares Outstanding | -4.53% | 0.33% | |||
| Average Diluted Shares Outstanding | 28.45% | 10.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||